The drug pricing debate in Washington has kicked back into high gear, and it is more contentious, convoluted and misguided than ever. Who’s on what team? Whose “turn” is next? And, most importantly, what is in the best interest of patients and taxpayers? These questions may sound rhetorical, but they’re questions that Congress should be asking.

By JC Scott, President and CEO, PCMA In the past few years, some have been pushing the narrative that pharmacy benefit companies are driving independent pharmacies out of business. Their argument seems compelling, but is it true? As we do

Congress has shown it has both the appetite and ability to enact prescription drug pricing policy.

So now we need those of us in the private market to do our part.

The Fourth of July. This is the most fundamental of American holidays, representing a celebration of our independence and our way of governing ourselves, giving us a moment to be grateful for what we have as a nation.

It should come as no surprise that pharmacy benefit managers (PBMs) applaud Congress for recent bipartisan action to further delay the rebate rule as part of legislation to address gun safety and mental health.

PBMs are proud of the work they do to reduce prescription drug costs, expand affordable access to medications, and improve patient outcomes.

I recently had the opportunity to participate in a listening forum at the Federal Trade Commission (FTC) on competition in the health care industry where I shared my thoughts on what needs to be done to make prescription drugs more affordable — a goal we firmly support.